Plain-English translation of NCT06883617 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage study testing the Lunair Alpha System, an implanted device designed to treat moderate to severe sleep apnea. Researchers want to see if this nerve stimulation device is safe and works well for people who have not done well with or cannot access other sleep apnea treatments. You would receive the implant and be monitored to see how it affects your sleep and breathing.
Many people with sleep apnea cannot tolerate or afford standard treatments like continuous positive airway pressure (CPAP) machines or oral devices. This trial exists to explore whether nerve stimulation could offer a new option for these patients.
You likely qualify if…
You likely don't qualify if…
You would undergo screening tests including a sleep study to confirm your diagnosis. If you qualify, you would receive surgical implantation of the Lunair Alpha System. After implant, you would attend follow-up visits so researchers can monitor your safety and measure how well the device works for your sleep apnea. The study involves approximately 45 participants total.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Paraguay
Sponsor
Lunair Medical
Enrollment target
~45 participants
Started
January 2025
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andrea Director of Clinical Operations
Lunair Medical
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.